Frailty, Mental Disorders, and Metabolic Syndrome: A Genetic Association 1

and Mediation Mendelian Randomization Study 2

- 3
- 4 Ming-Gang Deng^{1,2}, Kai Wang³, Jia-Qi Nie⁴, Fang Liu⁵, Yuehui Liang⁵, Jiewei Liu^{1,2}
- 5
- 6 ¹ Department of Psychiatry, Wuhan Mental Health Center, Wuhan 430012, Hubei, China
- 7 ² Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan 430012, Hubei, China
- 8 ³ Department of Public Health, Wuhan Fourth Hospital, Wuhan 430033, Hubei, China
- 9 ⁴ Xiaogan Center for Disease Control and Prevention, Xiaogan 432000, Hubei, China
- 10 ⁵ School of Public Health, Wuhan University, Wuhan 430071, Hubei, China
- 11
- 12 **Equal contribution:**
- 13 Ming-Gang Deng and Kai Wang.
- 14 **Correspondence:**
- 15 Ming-Gang Deng (deng.minggang@outlook.com)
- 16 Jiewei Liu (liujiewei@hust.edu.cn)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

17 Abstract

- 18 Objective: To examine the genetic associations of metabolic syndrome (MetS) with frailty and mental 19 disorders [depression, schizophrenia (SCZ), and bipolar disorder (BIP)], along with causality between frailty 20 and MetS and the mediating role of mental disorders. 21 Methods: The summary-level datasets were obtained from recent genome-wide association studies. The 22 genetic correlation was explored from the perspectives of global and local genetic correlation. Univariate 23 Mendelian Randomization (UMR) was used to investigate the causal link between frailty and metabolic 24 syndrome (MetS), followed by multivariate MR to address the confounding effects of body mass index 25 (BMI) and physical activity (PA). Finally, two-step MR analyses were conducted to examine whether the 26 causal relationship was mediated by mental disorders. 27 **Results:** The global genetic correlation analyses presented MetS was positively associated with frailty and 28 depression, but reversely related to SCZ. Similarly, MetS was locally correlated to frailty, depression, and 29 SCZ in numerous genomic regions. The UMR demonstrated that fragile people have a higher likelihood of 30 suffering from MetS (OR: 2.773, 95% CI: 1.455-5.286, p = 0.002), and reversely people with MetS tended to 31 be more fragile (beta: 0.211, 95% CI: 0.180-0.241, p < 0.001). This bidirectional causal association still 32 existed even after adjusting for BMI and PA. The mediation analyses implied this causality was mediated by 33 depression, but not SCZ and BIP. 34 Conclusion: Our research provided evidence of genetic correlations between MetS and frailty, depression,
- and SCZ. Additionally, we discovered a bidirectional causality between frailty and MetS, with depression
 playing a significant mediating role.
- 37 Keywords: frailty; metabolic syndrome; depression; Genetic association; Mendelian Randomization.

38 **1. Introduction**

39 Frailty, defined as a decrease in function across various physiological systems coupled with heightened sensitivity to stressors, is experiencing a significant rise due to the aging population (1). Concurrently, 40 frailty is linked to numerous negative health outcomes and a surge in healthcare expenditures (2; 3). 41 42 Metabolic syndrome (MetS), which was initially recognized as a prevalent metabolic disorder stemming 43 from the rise in obesity rates, is now acknowledged by the International Diabetes Federation as a 44 constellation of risk factors for cardiovascular diseases and type 2 diabetes (4). Its contribution to a range 45 of non-communicable chronic diseases results in a substantial disease burden, underscoring the 46 importance of early prevention.

47 The positive association between frailty and MetS has gained wide recognition through numerous 48 epidemiological studies. Notably, a meta-analysis comprising 11 observational studies revealed a 49 significant correlation between MetS and the occurrence of frailty (5). Furthermore, in a cohort study of 50 1,499 older adults free from diabetes at the outset, those with MetS were found to have a higher risk of 51 developing frailty (6). Additionally, findings from the Irish Longitudinal Study on Ageing indicated an 52 escalated risk of developing frailty over a period of four years associated with MetS (7). However, the 53 precise causative relationship between frailty and MetS remains insufficiently explored as the 54 observational study design was susceptible to confounding bias and reverse causality.

Recent research has shed light on the complex development of frailty and MetS, focusing on insulin resistance as a central explanatory factor. At the same time, studies have revealed a significant connection between insulin resistance and various mental health disorders, including depression(8), schizophrenia (SCZ)(9), and bipolar disorder (BIP)(10). Additionally, our previous study has shown the causal bidirectional causal association of frailty with depression and SCZ, leading to an in-depth exploration of the potential mediating role of mental health disorders in explaining the causal link between frailty and MetS. Ongoing

61 investigations into the mediating role of mental disorders have the potential to provide valuable insights

62 into the complex interconnections among these conditions.

Large-scale genome-wide association studies (GWASs) have identified numerous genetic loci associated with frailty, MetS, and mental disorders, which could enhance the statistical power and offer the opportunity to explore their genetic associations. In addition, Mendelian Randomization (MR), which uses genetic variants (single nucleotide polymorphisms, SNPs) as instruments, is a powerful method for obtaining robust causal inference and has been widely utilized in recent epidemiological research(11; 12). As a result, this study aimed to investigate the genetic association and causality between frailty and MetS and to check whether mental disorders played mediation roles.

70 2. Method and materials

71 2.1. Study design

An outline of the study design for this research is presented in **Fig 1**. The study was conducted in two parts: The first part involved exploring the genetic correlation of MetS with frailty and mental disorders through global and local genetic correlation analyses. The second part aimed to examine the causal relationship between frailty and MetS and determine whether mental disorders played a mediating role. The causal association between frailty and MetS was initially assessed via univariate MR (UMR) analyses, followed by multivariate MR (MVMR) analyses with adjustments for confounders. The mediating roles of mental disorders were evaluated through two-step MR analyses.

79 2.2. Data sources

The genetic variants associated with frailty were derived from a recent large-scale GWAS study of fried frailty scores, as delineated by the five criteria: weight loss, exhaustion, physical activity, walking speed, and grip strength(13). The study included 386,565 participants of European descent enrolled in the UK Biobank, whose average age was 57 years old and women made up 54% of the total.

The genetic data related to MetS are based on the latest study from the Complex Trait Genetics Lab (CTG), which contains 461,920 valid subjects of European ancestry(14). The researchers systematically analyzed genetic correlations of fasting glucose, high-density lipoprotein (HDL) cholesterol, systolic blood pressure, triglycerides, and waist circumference using the structural equation modeling method, and identified 235 loci related to MetS. For the mental disorders, we focused on depression, schizophrenia (SCZ), and bipolar disorder (BIP), which

were common and have been linked to MetS. Data related to depression was obtained from the Integrative Psychiatric Research (iPSYCH) consortium, which included 166,773 cases and 507,679 controls(15). The genetic data related to SCZ and BIP were retrieved from the Psychiatric Genomics Consortium (PGC). The GWAS of SCZ was composed of 52,017 individuals with SCZ and 75,889 controls(16), while the BIP data included 40,463 people with BIP and 313,436 controls(17).

95 2.3. Genetic association

We evaluated the genetic association of MetS with frailty and mental disorders from two perspectives: global and local genetic correlation. The global genetic correlation was calculated using linkage disequilibrium score regression (LDSC), which allowed us to assess the cross-trait genetic correlation from GWAS summary statistics. The estimate (r_g) varies from -1 to +1, with -1 indicating a complete negative correlation, and +1 representing a perfect positive correlation.

SUPERGNOVA (SUPER GeNetic cOVariance Analyzer), a statistical framework to perform local genetic correlation analysis, was used to quantify the genetic similarity of two traits in genomic regions. The algorithm partitions the entire genome into approximately 2,353 LD-independent blocks and offers a precise quantification of the similarity between pairs of traits influenced by genetic variations in each region. The statistical significance threshold for testing the local genetic correlation was corrected by the Bonferroni method.

107 2.4. Mendelian Randomization

108 2.4.1. Instrumental variants selection

SNPs were Initially screened utilizing a threshold of genome-wide significance ($p < 5 \times 10^{-8}$) to identify robust relationships with exposures. The F statistic was then calculated to determine if the SNPs were susceptible to weak instrument bias, and the instruments having an F statistic of less than 10 were eliminated.

113 Subsequently, the PLINK v1.9 was employed to clump for linkage disequilibrium (LD) with the European

samples from the 1000 Genome Project as the reference panel, and the clumping R² cutoff was set to 0.001

115 within a window size of 10,000 kb. If the LD effect was identified, only the SNP with the lowest *p*-value

116 would be kept.

We then harmonized the exposure and outcome datasets, where the palindromic SNPs were excluded. If any instrument was unavailable in the outcome data, it would be replaced by the proxied genetic variations (minimum LD $R^2 = 0.8$ and minor allele frequency threshold = 0.3). After the aforementioned procedures were completed, the remained SNPs were utilized for conducting the MR analysis.

121 2.4.2. Statistical analyses

122 We first performed the UMR to assess the causal relationship between frailty and MetS. The inverse 123 variance weighted (IVW) method was treated as the primary method to obtain the causal estimate. This 124 method assumes the presence of an average pleiotropic effect and is the most efficient method in this 125 case. Prior to performing the IVW analyses, Cochran's Q statistic was calculated to evaluate whether heterogeneity existed among the genetic variants. If significant heterogeneity was detected (p-value < 126 127 0.05), the causal effect would be estimated under the random-effect IVW method; otherwise, the 128 fixed-effect method would be used. In addition to the IVW method, three pleiotropy robust methods 129 including MR-Egger, weighted median, and MR-LASSO were employed to evaluate the stability of the

results. The leave-one-out (LOO) analyses and MR-Egger regression intercept term were respectively conducted to check whether the overall effect was driven by a single SNP or to assess the possible presence of horizontal pleiotropy.

133 Apart from the UMR, the MVMR analyses were conducted to obtain the causal inference with adjustments 134 for the confounding effect. MVMR as an extension of UMR, using genetic variants associated with multiple 135 and potentially related exposures, could detect the causal effects of multiple risk factors jointly. Before 136 performing the MVMR analyses, the PhenoScanner was employed to evaluate which confounders the 137 selected SNPs were associated with ($p < 1 \times 10^{-5}$). Body mass index (BMI) was discovered to be related to 138 the instrumental variants associated with frailty, as well as MetS. In addition to BMI, physical activity (PA) as 139 a common and easily modifiable lifestyle factor has been displayed to be associated with the risks of both 140 frailty and MetS. As a result, we estimated the causal effect between frailty and MetS with adjustments for 141 BMI and PA, and the IVW, MR-Egger, weighted median, and MR-LASSO methods were adopted. 142 Following the UMR and MVMR to assess the relationship between frailty and MetS, we applied the

143 two-step UMR analyses to explore whether the mental disorders could mediate this association. When 144 frailty was the exposure, the first step was to obtain the causal effect of frailty on mental disorders, while 145 the second step was to obtain the causal effect of mental disorders on MetS. As for the reverse analyses, 146 the first and second steps were to estimate the causal effects of MetS on mental disorders, and mental 147 disorders on frailty, respectively. Similar to the above MR analyses, the IVW Method was employed as the primary method for causal inference, and the MR-Egger, weighted median as well as MR-LASSO were 148 149 supplemented. The mediating effect proportions were calculated based on the estimates from the IVW method. 150

151 The MR analyses were conducted in in R software (version 4.3.1, R Foundation for Statistical Computing) 152 with related *TwoSampleMR* (version 0.5.8), and *MendelianRandomization* (version 0.9.0) packages. Effect 153 estimates were reported in β values with 95% confidence interval (CI) when the outcome was frailty and 7

- 154 were converted to odds ratio (OR) when the outcome was the others. All statistical tests were two-tailed,
- 155 and α = 0.05 was considered as the significant level.

156 **3. Results**

157 3.1. Genetic association analyses

158 The results of global genetic correlation analyses by the LDSC presented that genetically predicted MetS

- 159 was positively related to frailty ($r_g = 0.640$, se = 0.026, $p = 2.83 \times 10^{-134}$), depression ($r_g = 0.194$, se = 0.028, p
- 160 = 6.45×10^{-12}), and negatively related to SCZ ($r_g = -0.103$, se = 0.020, $p = 1.36 \times 10^{-7}$), but not correlated to
- 161 BIP ($r_g = -0.030$, se = 0.021, p = 0.157).

Similar to the global genetic correlation results, the local genetic correlation analyses demonstrated that MetS was locally correlated with frailty, depression, and SCZ, while no locally correlated genomic regions were identified between MetS and BIP (**Fig 2**). In particular, MetS was correlated with frailty in 18 genomic regions after correcting for multiple tests, and the estimates were all positive. Similarly, MetS was positively associated with depression in the three significant regions, while negatively related to SCZ in the 2 of 5 significant regions.

- 168 3.2. Mendelian Randomization analyses
- 169 3.2.1. Causal relationship between frailty and MetS

The results of UMR to obtain the causality between frailty and MetS are presented in **Table 1**. The Cochran's Q test indicated there was significant heterogeneity among the instruments related to frailty (Cochran's Q = 581.184, p < 0.001) and MetS (Cochran's Q = 649.002, p < 0.001). Therefore, the primary effect sizes were estimated by the random-effect IVW method. The IVW method showed that genetically predicted frailty was positively correlated with the risk of MetS (OR: 2.773, 95% CI: 1.455-5.286, p = 0.002), and this causality was supported by the weighted median (OR: 2.065, 95% CI: 1.692-2.519, p < 0.001), and MR-LASSO methods (OR: 1.994, 95% CI: 1.618-2.457, p < 0.001). The reverse analyses indicated that people

with MetS were meanwhile more likely to be fragile (beta = 0.211, 95% CI: 0.180-0.241, p < 0.001), and the supplementary methods including MR-Egger (beta: 0.185, 95% CI: 0.100-0.270, p < 0.001), weighted median (beta: 0.209, 95% CI: 0.173-0.244, p < 0.001), and MR-LASSO (beta: 0.232, 95% CI: 0.214-0.251, p < 0.001) presented similar estimates. Sensitivity analyses conducted by the MR-Egger regression intercept term presented there was no obvious horizontal pleiotropy among the SNPs related to frailty (p = 0.895) and MetS (p = 0.520), and the LOO analyses showed the bidirectional causal association between frailty and MetS were not driven by a single SNP (**Supplementary Fig S1 and Table S1**).

184 Afterward, the MVMR was conducted to determine the robustness of this bidirectional causal relationship 185 after accounting for the confounding effects of BMI and PA. The results are detailed in **Supplementary** 186 Table S2. After adjusting for BMI, the IVW method indicated that genetically predicted frailty was still 187 associated with a 61.0% higher likelihood of developing MetS (OR: 1.610, 95% CI: 1.275-2.034, p < 0.001). 188 Conversely, individuals with MetS were found to be more fragile (beta: 0.171, 95% CI: 0.119-0.224, p <189 0.001). The bidirectional causal association was confirmed by the MR-Egger, weighted median, and 190 MR-LASSO methods. Furthermore, this correlation persisted even after controlling for PA, which was 191 corroborated by the four methods.

192 3.2.2. Mediating role of mental disorders

By utilizing the two-step MR analyses, we assessed whether mental disorders could mediate the bidirectional causality between frailty and MetS. The results are presented in **Fig 3** and **Supplementary**

195 Table S3-S4.

For the forward analyses, genetically predicted frailty was positively correlated with the risk the depression (OR: 2.815, 95% CI: 1.639, 4.836, p < 0.001), SCZ (OR: 2.230, 95% CI: 1.093, 4.549, p = 0.028), and depressed individuals have a higher likelihood to developing MetS (OR: 1.235, 95% CI: 1.099, 1.388, p < 0.001).

However, no other significant causal associations were discovered. Therefore, depression exerted amediation role in the causal effect of frailty and MetS.

In the reverse analyses, it was found that individuals with MetS were discovered were more likely to suffer from depression (OR: 1.226, 95% CI: 1.117, 1.347, p < 0.001), but not SCZ and BIP. Besides, people with depression (beta: 0.185, 95% CI: 0.144, 0.226, p < 0.001) and SCZ (beta: 0.015, 95% CI: 0.005, 0.024, p =0.002) were more likely to be frail. Similarly, the causal effect of MetS on frailty was mediated by depression.

206 **4. Discussion**

207 Our study investigated the genetic associations of MetS with frailty and mental disorders, along with the 208 causative relationship between frailty and MetS, and the mediating effects of mental disorders. Our 209 research furnished evidence of genetic correlations between MetS and frailty, depression, and SCZ. 210 Furthermore, we uncovered a bidirectional causality between frailty and MetS, with depression playing a 211 significant mediating role.

212 While Barzilay et al. found no association between MetS and incident frailty(18), most studies confirm a 213 significant link(5; 19). Meanwhile, a similar study by Jiahao Zhu et al. demonstrates the bidirectional causal 214 association of frailty with cardiometabolic diseases, including coronary artery disease, stroke, and type 2 215 diabetes(20). Nevertheless, MetS in the current study did not fully align with cardiometabolic diseases. 216 Collectively, frailty and MetS exhibit associations rooted in the various components of MetS, evidenced by 217 abdominal obesity(21), high blood pressure(22), remnant cholesterol(23), and low HDL-cholesterol(24). In 218 addition to the above factors, the U-shape association of serum glucose level and frailty was determined 219 in older adults without diabetes(25).

220 Contemporary researchers are increasingly delving into the molecular mechanisms underlying both frailty
 221 and MetS, uncovering shared pathogenic pathways. One prominently explored commonality is insulin

222 resistance, recognized as a pivotal factor in both conditions. Emerging evidence underscores the pivotal 223 role of insulin-like growth factor (IGF) in the hypothalamic-pituitary axis(26), contributing to frailty 224 through reduced muscle protein synthesis, involving the Akt signaling pathway and AMP-activated protein 225 kinase(27). Meanwhile, insulin plays a crucial role in muscle protein synthesis and maintenance while 226 insulin resistance impaired relevant signaling pathways to reduce muscle protein synthesis and increase 227 the breakdown of muscle tissue, leading to the development of frailty. Therefore, insulin resistance as the 228 central feature of MetS is acknowledged as a precursor to frailty(26), prompting investigations into it as a 229 target for prevention(28).

230 Vitamin D (VD), essential for bone health and calcium metabolism, is correlated with frailty by tremendous 231 longitudinal studies and randomized controlled trials(29; 30). Besides, the VD/VD receptor axis regulate 232 biological processes including proteolysis, mitochondrial function, cellular senescence, and adiposity(31), 233 contributing to sarcopenic muscle atrophy and subsequent frailty. Furthermore, the relationship between 234 VD deficiency and MetS was approved by plenty of studies in adults and children, and one of the potential 235 mechanisms is the effect of VD on insulin secretion and sensitivity(32). VD could improve insulin resistance 236 and VD deficiency compromises the capacity of pancreatic β cells to convert pro-insulin into insulin, while 237 insulin serves as a vital factor in the prevention of MetS. Another recent plausible explanation is the gut 238 microbiota-bile acid axis possibly through the modulation of the PPAR signaling pathway, as evidenced to 239 mediate the relationship between plasma VD and MetS in 2966 Chinese participants with a 9-year 240 follow-up(33). Hence, VD emerges as a potential link between frailty and MetS.

Oxidative stress and inflammation play parallel roles in frailty and MetS through various aspects and pathways. Oxidative stress is closely linked to aging while the most notable manifestation of aging is the clinical condition of frailty. Both meta-analyses and mouse models(34) provided robust evidence of oxidative stress and chronic inflammation as relevant biomarkers and precursors of frailty. Oxidative stress, characterized by excessive reactive oxygen species production, oxidized lipids to produce lipid peroxides, 11

disrupted redox signaling and activated the apoptosis pathway. Moreover, oxidative stress affects insulin
 metabolic signaling and promotes cardiovascular and renal inflammation and fibrosis, resulting in damage
 to relevant organs and subsequent MetS(35). The NF-κB signaling pathway, the major regulator of the
 proinflammatory response, suppresses insulin metabolic signaling and promotes in establishment a
 low-grade chronic inflammatory state, leading to subsequent metabolic damage(36).

251 In addition to the aforementioned explanations, our investigation extended to include depression, SCZ, 252 and BIP, aiming to scrutinize the mediating impact of these mental disorders. The results underscored a 253 significant mediation effect, particularly notable in the case of depression. Depression emerges as a 254 prevalent factor among individuals affected by frailty and MetS, and insulin resistance is implicated as a 255 crucial contributor to the intricate relationship between frailty, MetS, and the manifestation of depressive 256 symptoms. Supporting this exploration, a meta-analysis of 70 studies and over 240 million participants 257 elucidated a noteworthy positive association between the insulin resistance index and acute depression, 258 and this index remained unaltered even when depression symptoms were alleviated (37). Delving deeper 259 into the molecular mechanisms, insulin resistance was identified as a key player in altering central 260 dopaminergic signaling, particularly in the ventral tegmental area associated with reward behavior(38), 261 contributing to the development of anhedonia and depression. Specifically, insulin resistance was found to 262 diminish the synthesis and reuptake of dopamine through attenuated AKT signaling pathways, while the 263 dysregulation of dopamine intensively promotes the pathophysiologic development of depression(39).

Our study had several noteworthy strengths. Firstly, we utilized genetic variants from large-scale GWASs, which enhanced the statistical power to detect genetic associations. Additionally, by using genetic variants as instruments, Mendelian randomization (MR) could provide valid causal inference, overcoming the limitations of conventional observational studies, such as confounding bias and reverse causality. Moreover, our study focused on mental disorders and highlighted the mediating role of depression in the relationship between frailty and MetS.

270	While our study has these advantages, it should be considered within the context of its limitations. Firstly,
271	the participants in this research were all of European ancestry, which may limit the generalizability of our
272	findings. Secondly, the different methods used to assess frailty may also influence the results. The frailty
273	index (FI) was another frequently used tool to evaluate an individual's frailty status, and the recent GWAS
274	has discovered 14 loci related to FL(40). We did not use this index out of concern for biased causal
275	inference, as high blood pressure, lipid disorder, and diabetes were important scoring items for FL and, at
276	the same time, the main diagnostic criteria for MetS.

277 **5. Conclusion**

- Our research provided evidence of genetic correlations between MetS and frailty, depression, and SCZ.
 Additionally, we discovered a bidirectional causality between frailty and MetS, with depression playing a
 significant mediating role.
- 281 6. Declarations

282 Ethics approval

- 283 The data sets used in this research were publicly available from the published articles, and the ethics
- approvals were obtained in the original research.

285 Author contributions

- 286 Ming-Gang Deng: Conceptualization, Methodology, Data Curation, Formal Analysis, and Writing -
- 287 Original Draft; Kai Wang: Writing Original Draft; Jia-Qi Nie, Fang Liu, and Yuehui Liang: Writing -
- 288 Review & Editing; Jiewei Liu: Conceptualization, and Formal Analysis.
- 289 Acknowledgments
- 290 None.
- 291 Funding
- 292 The authors received no external funding.
 - 13

293 Competing interests

294 The authors declare that they have no competing interests

295 Data and code availability

- 296 The datasets utilized in this study are accessible on the IEU OpenGWAS project (https://gwas.mrcie
- 297 u.ac.uk/), figshare (https://figshare.com/s/6683396c68807fe4e729), PGC (https://pgc.unc.edu/for-resear
- 298 chers/download-results/), and *iPSYCH* (https://ipsych.dk/en/research/downloads).
- Additionally, the code employed in this study is also available: *ldscr* (https://github.com/mglev1n/lds
- 300 cr), SUPERGNOVA (https://github.com/qlu-lab/SUPERGNOVA), TwoSampleMR (https://mrcieu.github.io
- 301 /TwoSampleMR/), and MendelianRandomization (https://github.com/cran/MendelianRandomization).

302 **7. Reference**

- 303 1. Hoogendijk EO, Afilalo J, Ensrud KE, Kowal P, Onder G, Fried LP. Frailty: implications for clinical practice
 304 and public health. Lancet (London, England) 2019;394:1365-1375
- Ward DD, Ranson JM, Wallace LMK, Llewellyn DJ, Rockwood K. Frailty, lifestyle, genetics and dementia
 risk. Journal of neurology, neurosurgery, and psychiatry 2022;93:343-350
- 307 3. Hajek A, Bock JO, Saum KU, Matschinger H, Brenner H, Holleczek B, Haefeli WE, Heider D, König HH.
- 308 Frailty and healthcare costs-longitudinal results of a prospective cohort study. Age and ageing 309 2018;47:233-241
- 4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM,
- 311 Smith SC, Jr. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes
- 312 Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute;
- 313 American Heart Association; World Heart Federation; International Atherosclerosis Society; and
- 314 International Association for the Study of Obesity. Circulation 2009;120:1640-1645
- 5. Jiang X, Xu X, Ding L, Lu J, Zhu H, Zhao K, Zhu S, Xu Q. The association between metabolic syndrome and
- 316 presence of frailty: a systematic review and meta-analysis. European geriatric medicine 2022;13:1047-1056

6. Pé rez-Tasigchana RF, Le ó n-Muñoz LM, Lopez-Garcia E, Gutierrez-Fisac JL, Laclaustra M, Rodrí
guez-Artalejo F, Guallar-Castillón P. Metabolic syndrome and insulin resistance are associated with frailty in
older adults: a prospective cohort study. Age and ageing 2017;46:807-812

320 7. McCarthy K, Laird E, O'Halloran AM, Fallon P, Ortuño RR, Kenny RA. Association between metabolic 321 syndrome and risk of both prevalent and incident frailty in older adults: Findings from The Irish

322 Longitudinal Study on Ageing (TILDA). Experimental gerontology 2023;172:112056

323 8. Sen ZD, Danyeli LV, Woelfer M, Lamers F, Wagner G, Sobanski T, Walter M. Linking atypical depression

324 and insulin resistance-related disorders via low-grade chronic inflammation: Integrating the phenotypic,

325 molecular and neuroanatomical dimensions. Brain, behavior, and immunity 2021;93:335-352

326 9. Perry BI, Burgess S, Jones HJ, Zammit S, Upthegrove R, Mason AM, Day FR, Langenberg C, Wareham NJ,

327 Jones PB, Khandaker GM. The potential shared role of inflammation in insulin resistance and schizophrenia:

A bidirectional two-sample mendelian randomization study. PLoS medicine 2021;18:e1003455

329 10. Miola A, Alvarez-Villalobos NA, Ruiz-Hernandez FG, De Filippis E, Veldic M, Prieto ML, Singh B, Sanchez

330 Ruiz JA, Nunez NA, Resendez MG, Romo-Nava F, McElroy SL, Ozerdem A, Biernacka JM, Frye MA,

331 Cuellar-Barboza AB. Insulin resistance in bipolar disorder: A systematic review of illness course and clinical

332 correlates. Journal of affective disorders 2023;334:1-11

11. Deng MG, Liu F, Liang Y, Wang K, Nie JQ, Liu J. Association between frailty and depression: A
 bidirectional Mendelian randomization study. Science advances 2023;9:eadi3902

12. Deng MG, Cui HT, Nie JQ, Liang Y, Chai C. Genetic association between circulating selenium level and

the risk of schizophrenia in the European population: A two-sample Mendelian randomization study.

337 Frontiers in nutrition 2022;9:969887

338 13. Ye Y, Noche RB, Szejko N, Both CP, Acosta JN, Leasure AC, Brown SC, Sheth KN, Gill TM, Zhao H, Falcone
339 GJ. A genome-wide association study of frailty identifies significant genetic correlation with
a40 neuropsychiatric, cardiovascular, and inflammation pathways. GeroScience 2023;45:2511-2523

14. van Walree ES, Jansen IE, Bell NY, Savage JE, de Leeuw C, Nieuwdorp M, van der Sluis S, Posthuma D.
Disentangling Genetic Risks for Metabolic Syndrome. Diabetes 2022;71:2447-2457

15. Als TD, Kurki MI, Grove J, Voloudakis G, Therrien K, Tasanko E, Nielsen TT, Naamanka J, Veerapen K,

Levey DF, Bendl J, Bybjerg-Grauholm J, Zeng B, Demontis D, Rosengren A, Athanasiadis G, Bækved-Hansen

345 M, Qvist P, Bragi Walters G, Thorgeirsson T, Stefánsson H, Musliner KL, Rajagopal VM, Farajzadeh L,

Thirstrup J, Vilhjálmsson BJ, McGrath JJ, Mattheisen M, Meier S, Agerbo E, Stefánsson K, Nordentoft M,
 15

Werge T, Hougaard DM, Mortensen PB, Stein MB, Gelernter J, Hovatta I, Roussos P, Daly MJ, Mors O, Palotie
A, Børglum AD. Depression pathophysiology, risk prediction of recurrence and comorbid psychiatric
disorders using genome-wide analyses. Nature medicine 2023;29:1832-1844

350 16. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, Bryois J, Chen CY, Dennison 351 CA, Hall LS, Lam M, Watanabe K, Frei O, Ge T, Harwood JC, Koopmans F, Magnusson S, Richards AL, 352 Sidorenko J, Wu Y, Zeng J, Grove J, Kim M, Li Z, Voloudakis G, Zhang W, Adams M, Agartz I, Atkinson EG, 353 Agerbo E, Al Eissa M, Albus M, Alexander M, Alizadeh BZ, Alptekin K, Als TD, Amin F, Arolt V, Arrojo M, 354 Athanasiu L, Azevedo MH, Bacanu SA, Bass NJ, Begemann M, Belliveau RA, Bene J, Benyamin B, Bergen SE, 355 Blasi G, Bobes J, Bonassi S, Braun A, Bressan RA, Bromet EJ, Bruggeman R, Buckley PF, Buckner RL, 356 Bybjerg-Grauholm J, Cahn W, Cairns MJ, Calkins ME, Carr VJ, Castle D, Catts SV, Chambert KD, Chan RCK, Chaumette B, Cheng W, Cheung EFC, Chong SA, Cohen D, Consoli A, Cordeiro Q, Costas J, Curtis C, 357 Davidson M, Davis KL, de Haan L, Degenhardt F, DeLisi LE, Demontis D, Dickerson F, Dikeos D, Dinan T, 358 359 Djurovic S, Duan J, Ducci G, Dudbridge F, Eriksson JG, Fañanás L, Faraone SV, Fiorentino A, Forstner A, Frank 360 J, Freimer NB, Fromer M, Frustaci A, Gadelha A, Genovese G, Gershon ES, Giannitelli M, Giegling I, 361 Giusti-Rodríguez P, Godard S, Goldstein JI, González Peñas J, González-Pinto A, Gopal S, Gratten J, Green 362 MF, Greenwood TA, Guillin O, Gülöksüz S, Gur RE, Gur RC, Gutiérrez B, Hahn E, Hakonarson H, Haroutunian 363 V, Hartmann AM, Harvey C, Hayward C, Henskens FA, Herms S, Hoffmann P, Howrigan DP, Ikeda M, Iyegbe C, Joa I, Julià A, Kähler AK, Kam-Thong T, Kamatani Y, Karachanak-Yankova S, Kebir O, Keller MC, Kelly BJ, 364 365 Khrunin A, Kim SW, Klovins J, Kondratiev N, Konte B, Kraft J, Kubo M, Kučinskas V, Kučinskiene ZA, 366 Kusumawardhani A, Kuzelova-Ptackova H, Landi S, Lazzeroni LC, Lee PH, Legge SE, Lehrer DS, Lencer R, 367 Lerer B, Li M, Lieberman J, Light GA, Limborska S, Liu CM, Lönnqvist J, Loughland CM, Lubinski J, Luykx JJ, 368 Lynham A, Macek M, Jr., Mackinnon A, Magnusson PKE, Maher BS, Maier W, Malaspina D, Mallet J, Marder 369 SR, Marsal S, Martin AR, Martorell L, Mattheisen M, McCarley RW, McDonald C, McGrath JJ, Medeiros H, 370 Meier S, Melegh B, Melle I, Mesholam-Gately RI, Metspalu A, Michie PT, Milani L, Milanova V, Mitjans M, 371 Molden E, Molina E, Molto MD, Mondelli V, Moreno C, Morley CP, Muntané G, Murphy KC, Myin-Germeys I, 372 Nenadić I, Nestadt G, Nikitina-Zake L, Noto C, Nuechterlein KH, O'Brien NL, O'Neill FA, Oh SY, Olincy A, 373 Ota VK, Pantelis C, Papadimitriou GN, Parellada M, Paunio T, Pellegrino R, Periyasamy S, Perkins DO, 374 Pfuhlmann B, Pietiläinen O, Pimm J, Porteous D, Powell J, Quattrone D, Quested D, Radant AD, Rampino A, 375 Rapaport MH, Rautanen A, Reichenberg A, Roe C, Roffman JL, Roth J, Rothermundt M, Rutten BPF, 376 Saker-Delye S, Salomaa V, Sanjuan J, Santoro ML, Savitz A, Schall U, Scott RJ, Seidman LJ, Sharp SI, Shi J, 16

377 Siever LJ, Sigurdsson E, Sim K, Skarabis N, Slominsky P, So HC, Sobell JL, Söderman E, Stain HJ, Steen NE, 378 Steixner-Kumar AA, Stögmann E, Stone WS, Straub RE, Streit F, Strengman E, Stroup TS, Subramaniam M, 379 Sugar CA, Suvisaari J, Svrakic DM, Swerdlow NR, Szatkiewicz JP, Ta TMT, Takahashi A, Terao C, Thibaut F, 380 Toncheva D, Tooney PA, Torretta S, Tosato S, Tura GB, Turetsky BI, Üçok A, Vaaler A, van Amelsvoort T, van 381 Winkel R, Veijola J, Waddington J, Walter H, Waterreus A, Webb BT, Weiser M, Williams NM, Witt SH, 382 Wormley BK, Wu JQ, Xu Z, Yolken R, Zai CC, Zhou W, Zhu F, Zimprich F, Atbaşoğlu EC, Ayub M, Benner C, 383 Bertolino A, Black DW, Bray NJ, Breen G, Buccola NG, Byerley WF, Chen WJ, Cloninger CR, Crespo-Facorro B, 384 Donohoe G, Freedman R, Galletly C, Gandal MJ, Gennarelli M, Hougaard DM, Hwu HG, Jablensky AV, 385 McCarroll SA, Moran JL, Mors O, Mortensen PB, Müller-Myhsok B, Neil AL, Nordentoft M, Pato MT, 386 Petryshen TL, Pirinen M, Pulver AE, Schulze TG, Silverman JM, Smoller JW, Stahl EA, Tsuang DW, Vilella E, 387 Wang SH, Xu S, Adolfsson R, Arango C, Baune BT, Belangero SI, Børglum AD, Braff D, Bramon E, Buxbaum 388 JD, Campion D, Cervilla JA, Cichon S, Collier DA, Corvin A, Curtis D, Forti MD, Domenici E, Ehrenreich H, 389 Escott-Price V, Esko T, Fanous AH, Gareeva A, Gawlik M, Gejman PV, Gill M, Glatt SJ, Golimbet V, Hong KS, 390 Hultman CM, Hyman SE, Iwata N, Jönsson EG, Kahn RS, Kennedy JL, Khusnutdinova E, Kirov G, Knowles JA, 391 Krebs MO, Laurent-Levinson C, Lee J, Lencz T, Levinson DF, Li QS, Liu J, Malhotra AK, Malhotra D, McIntosh 392 A, McQuillin A, Menezes PR, Morgan VA, Morris DW, Mowry BJ, Murray RM, Nimgaonkar V, Nöthen MM, 393 Ophoff RA, Paciga SA, Palotie A, Pato CN, Qin S, Rietschel M, Riley BP, Rivera M, Rujescu D, Saka MC, 394 Sanders AR, Schwab SG, Serretti A, Sham PC, Shi Y, St Clair D, Stefánsson H, Stefansson K, Tsuang MT, van 395 Os J, Vawter MP, Weinberger DR, Werge T, Wildenauer DB, Yu X, Yue W, Holmans PA, Pocklington AJ, 396 Roussos P, Vassos E, Verhage M, Visscher PM, Yang J, Posthuma D, Andreassen OA, Kendler KS, Owen MJ, 397 Wray NR, Daly MJ, Huang H, Neale BM, Sullivan PF, Ripke S, Walters JTR, O'Donovan MC. Mapping 398 genomic loci implicates genes and synaptic biology in schizophrenia. Nature 2022;604:502-508

399 17. Mullins N, Forstner AJ, O'Connell KS, Coombes B, Coleman JRI, Qiao Z, Als TD, Bigdeli TB, Børte S, 400 Bryois J, Charney AW, Drange OK, Gandal MJ, Hagenaars SP, Ikeda M, Kamitaki N, Kim M, Krebs K, 401 Panagiotaropoulou G, Schilder BM, Sloofman LG, Steinberg S, Trubetskoy V, Winsvold BS, Won HH, 402 Abramova L, Adorjan K, Agerbo E, Al Eissa M, Albani D, Alliey-Rodriguez N, Anjorin A, Antilla V, Antoniou A, 403 Awasthi S, Baek JH, Bækvad-Hansen M, Bass N, Bauer M, Beins EC, Bergen SE, Birner A, Bøcker Pedersen C, 404 Bøen E, Boks MP, Bosch R, Brum M, Brumpton BM, Brunkhorst-Kanaan N, Budde M, Bybjerg-Grauholm J, 405 Byerley W, Cairns M, Casas M, Cervantes P, Clarke TK, Cruceanu C, Cuellar-Barboza A, Cunningham J, Curtis 406 D, Czerski PM, Dale AM, Dalkner N, David FS, Degenhardt F, Djurovic S, Dobbyn AL, Douzenis A, 17

407 Elvsåshagen T, Escott-Price V, Ferrier IN, Fiorentino A, Foroud TM, Forty L, Frank J, Frei O, Freimer NB, Frisé 408 n L, Gade K, Garnham J, Gelernter J, Giørtz Pedersen M, Gizer IR, Gordon SD, Gordon-Smith K, Greenwood 409 TA, Grove J, Guzman-Parra J, Ha K, Haraldsson M, Hautzinger M, Heilbronner U, Hellgren D, Herms S, 410 Hoffmann P, Holmans PA, Huckins L, Jamain S, Johnson JS, Kalman JL, Kamatani Y, Kennedy JL, 411 Kittel-Schneider S, Knowles JA, Kogevinas M, Koromina M, Kranz TM, Kranzler HR, Kubo M, Kupka R, 412 Kushner SA, Lavebratt C, Lawrence J, Leber M, Lee HJ, Lee PH, Levy SE, Lewis C, Liao C, Lucae S, Lundberg M, 413 MacIntyre DJ, Magnusson SH, Maier W, Maihofer A, Malaspina D, Maratou E, Martinsson L, Mattheisen M, 414 McCarroll SA, McGregor NW, McGuffin P, McKay JD, Medeiros H, Medland SE, Millischer V, Montgomery 415 GW, Moran JL, Morris DW, Mühleisen TW, O'Brien N, O'Donovan C, Olde Loohuis LM, Oruc L, Papiol S, 416 Pardiñas AF, Perry A, Pfennig A, Porichi E, Potash JB, Quested D, Raj T, Rapaport MH, DePaulo JR, Regeer EJ, 417 Rice JP, Rivas F, Rivera M, Roth J, Roussos P, Ruderfer DM, Sánchez-Mora C, Schulte EC, Senner F, Sharp S, Shilling PD, Sigurdsson E, Sirignano L, Slaney C, Smeland OB, Smith DJ, Sobell JL, Søholm Hansen C, Soler 418 419 Artigas M, Spijker AT, Stein DJ, Strauss JS, Świątkowska B, Terao C, Thorgeirsson TE, Toma C, Tooney P, 420 Tsermpini EE, Vawter MP, Vedder H, Walters JTR, Witt SH, Xi S, Xu W, Yang JMK, Young AH, Young H, Zandi 421 PP, Zhou H, Zillich L, Adolfsson R, Agartz I, Alda M, Alfredsson L, Babadjanova G, Backlund L, Baune BT, 422 Bellivier F, Bengesser S, Berrettini WH, Blackwood DHR, Boehnke M, Børglum AD, Breen G, Carr VJ, Catts S, 423 Corvin A, Craddock N, Dannlowski U, Dikeos D, Esko T, Etain B, Ferentinos P, Frye M, Fullerton JM, Gawlik M, 424 Gershon ES, Goes FS, Green MJ, Grigoroiu-Serbanescu M, Hauser J, Henskens F, Hillert J, Hong KS, 425 Hougaard DM, Hultman CM, Hveem K, Iwata N, Jablensky AV, Jones I, Jones LA, Kahn RS, Kelsoe JR, Kirov G, 426 Landén M, Leboyer M, Lewis CM, Li QS, Lissowska J, Lochner C, Loughland C, Martin NG, Mathews CA, 427 Mayoral F, McElroy SL, McIntosh AM, McMahon FJ, Melle I, Michie P, Milani L, Mitchell PB, Morken G, Mors 428 O, Mortensen PB, Mowry B, Müller-Myhsok B, Myers RM, Neale BM, Nievergelt CM, Nordentoft M, Nöthen 429 MM, O'Donovan MC, Oedegaard KJ, Olsson T, Owen MJ, Paciga SA, Pantelis C, Pato C, Pato MT, Patrinos GP, 430 Perlis RH, Posthuma D, Ramos-Quiroga JA, Reif A, Reininghaus EZ, Ribasés M, Rietschel M, Ripke S, 431 Rouleau GA, Saito T, Schall U, Schalling M, Schofield PR, Schulze TG, Scott LJ, Scott RJ, Serretti A, Shannon 432 Weickert C, Smoller JW, Stefansson H, Stefansson K, Stordal E, Streit F, Sullivan PF, Turecki G, Vaaler AE, 433 Vieta E, Vincent JB, Waldman ID, Weickert TW, Werge T, Wray NR, Zwart JA, Biernacka JM, Nurnberger JI, 434 Cichon S, Edenberg HJ, Stahl EA, McQuillin A, Di Florio A, Ophoff RA, Andreassen OA. Genome-wide 435 association study of more than 40,000 bipolar disorder cases provides new insights into the underlying 436 biology. Nature genetics 2021;53:817-829

- 437 18. Barzilay JI, Blaum C, Moore T, Xue QL, Hirsch CH, Walston JD, Fried LP. Insulin resistance and
 438 inflammation as precursors of frailty: the Cardiovascular Health Study. Archives of internal medicine
 439 2007;167:635-641
- 440 19. Dao HHH, Burns MJ, Kha R, Chow CK, Nguyen TN. The Relationship between Metabolic Syndrome and
- 441 Frailty in Older People: A Systematic Review and Meta-Analysis. Geriatrics (Basel, Switzerland) 2022;7
- 20. Zhu J, Zhou D, Wang J, Yang Y, Chen D, He F, Li Y. Frailty and cardiometabolic diseases: a bidirectional
 Mendelian randomisation study. Age and ageing 2022;51
- 444 21. Yuan L, Chang M, Wang J. Abdominal obesity, body mass index and the risk of frailty in
 445 community-dwelling older adults: a systematic review and meta-analysis. Age and ageing
 446 2021;50:1118-1128
- 447 22. Liu P, Li Y, Zhang Y, Mesbah SE, Ji T, Ma L. Frailty and hypertension in older adults: current 448 understanding and future perspectives. Hypertension research : official journal of the Japanese Society of
- 449 Hypertension 2020;43:1352-1360
- 450 23. Hu Y, Wang X, Lin L, Huan J, Li Y, Zhang L, Li Y. Association of remnant cholesterol with frailty: findings
 451 from observational and Mendelian randomization analyses. Lipids in health and disease 2023;22:115
- 452 24. Bastos-Barbosa RG, Ferriolli E, Coelho EB, Moriguti JC, Nobre F, Lima NK. Association of frailty
- 453 syndrome in the elderly with higher blood pressure and other cardiovascular risk factors. American journal
- 454 of hypertension 2012;25:1156-1161
- 455 25. Zaslavsky O, Walker RL, Crane PK, Gray SL, Larson EB. Glucose Levels and Risk of Frailty. The journals of 456 gerontology Series A, Biological sciences and medical sciences 2016;71:1223-1229
- 457 26. Leng SX, Hung W, Cappola AR, Yu Q, Xue QL, Fried LP. White blood cell counts, insulin-like growth
- 458 factor-1 levels, and frailty in community-dwelling older women. The journals of gerontology Series A,
- 459 Biological sciences and medical sciences 2009;64:499-502
- 460 27. Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between
- 461 common co-morbidities. The Journal of endocrinology 2016;229:R67-81
- 462 28. Sundell J. Resistance Training Is an Effective Tool against Metabolic and Frailty Syndromes. Advances in
- 463 preventive medicine 2011;2011:984683
- 464 29. Dai M, Yue J, Zhang J, Wang H, Wu C. Functional dentition is a modifier of the association between
- vitamin D and the frailty index among Chinese older adults: a population-based longitudinal study. BMC
- 466 geriatrics 2022;22:159
 - 19

- 467 30. Bo Y, Liu C, Ji Z, Yang R, An Q, Zhang X, You J, Duan D, Sun Y, Zhu Y, Cui H, Lu Q. A high whey protein,
- 468 vitamin D and E supplement preserves muscle mass, strength, and quality of life in sarcopenic older adults:
- 469 A double-blind randomized controlled trial. Clinical nutrition (Edinburgh, Scotland) 2019;38:159-164
- 470 31. Bollen SE, Bass JJ, Fujita S, Wilkinson D, Hewison M, Atherton PJ. The Vitamin D/Vitamin D receptor
- 471 (VDR) axis in muscle atrophy and sarcopenia. Cellular signalling 2022;96:110355
- 472 32. Xia Y, Yu Y, Zhao Y, Deng Z, Zhang L, Liang G. Insight into the Interaction Mechanism of Vitamin D
- 473 against Metabolic Syndrome: A Meta-Analysis and In Silico Study. Foods (Basel, Switzerland) 2023;12
- 474 33. Lin HR, Xu F, Chen D, Xie K, Yang Y, Hu W, Li BY, Jiang Z, Liang Y, Tang XY, Zheng JS, Chen YM. The gut
- 475 microbiota-bile acid axis mediates the beneficial associations between plasma vitamin D and metabolic
- 476 syndrome in Chinese adults: A prospective study. Clinical nutrition (Edinburgh, Scotland) 2023;42:887-898
- 477 34. Álvarez-Satta M, Berna-Erro A, Carrasco-Garcia E, Alberro A, Saenz-Antoñanzas A, Vergara I, Otaegui D,
- 478 Matheu A. Relevance of oxidative stress and inflammation in frailty based on human studies and mouse
- 479 models. Aging 2020;12:9982-9999
- 480 35. Masenga SK, Kabwe LS, Chakulya M, Kirabo A. Mechanisms of Oxidative Stress in Metabolic Syndrome.
- 481 International journal of molecular sciences 2023;24
- 482 36. Catrysse L, van Loo G. Inflammation and the Metabolic Syndrome: The Tissue-Specific Functions of NF-
- 483 κB. Trends in cell biology 2017;27:417-429
- 484 37. Fernandes BS, Salagre E, Enduru N, Grande I, Vieta E, Zhao Z. Insulin resistance in depression: A large
 485 meta-analysis of metabolic parameters and variation. Neuroscience and biobehavioral reviews
 486 2022;139:104758
- 38. Gruber J, Hanssen R, Qubad M, Bouzouina A, Schack V, Sochor H, Schiweck C, Aichholzer M, Matura S,
 Slattery DA, Zopf Y, Borgland SL, Reif A, Thanarajah SE. Impact of insulin and insulin resistance on brain
 dopamine signalling and reward processing An underexplored mechanism in the pathophysiology of
 depression? Neuroscience and biobehavioral reviews 2023;149:105179
- 491 39. Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and
 492 depression. Nature reviews Neuroscience 2016;17:524-532
- 493 40. Atkins JL, Jylhävä J, Pedersen NL, Magnusson PK, Lu Y, Wang Y, Hägg S, Melzer D, Williams DM, Pilling
 494 LC. A genome-wide association study of the frailty index highlights brain pathways in ageing. Aging cell
 495 2021;20:e13459
- 496

497 Table 1. Univariate causal inference between frailty and metabolic syndrome

						<i>p</i> -value for heterogeneity*
Exposure	Outcome	Method	beta / OR (95% CI)	<i>p</i> -value	Cochran's Q	or pleiotropy†
Frailty	MetS	IVW	2.773 (1.455, 5.286)	0.002	581.184	<0.001
		MR-Egger	2.337 (0.179, 30.447)	0.517		0.895
		Weighted Median	2.065 (1.692, 2.519)	<0.001		
		MR-LASSO	1.994 (1.618, 2.457)	<0.001		
MetS	Frailty	IVW	0.211 (0.18, 0.241)	<0.001	649.002	<0.001
		MR-Egger	0.185 (0.100, 0.270)	<0.001		0.520
		Weighted Median	0.209 (0.173, 0.244)	<0.001		
		MR-LASSO	0.232 (0.214, 0.251)	< 0.001		

Abbreviations: OR, odds ratio; MetS, metabolic syndrome; IVW, inverse variance weighted. 498

499 **p*-value for heterogeneity based on Cochran's Q statistic.

500 [†]*p*-value or pleiotropy based on MR-Egger regression intercept.

501 Figure Lege	end
-----------------	-----

502

- 503 Fig 1. Study overview.
- 504 Abbreviations: MetS, metabolic syndrome; SCZ, schizophrenia; BIP, bipolar disorder; SNPs, single
- 505 nucleotide polymorphisms; BMI, body mass index; PA, physical activity.

506

- 507 Fig 2. The results of local genetic correlation. The red dotted line represents the corrected significance
- 508 threshold, the purple points indicate negatively correlated regions, and the black points were positively
- 509 correlated regions.
- 510 Abbreviations: MetS, metabolic syndrome; SCZ, schizophrenia; BIP, bipolar disorder

511

512 Fig 3. Depression mediated the bidirectional causality between frailty and metabolic syndrome.







Multivariate Mendelian Randomization



Mediation Mendelian Randomization

Forward

Reverse







